Journal of Chemotherapy最新文献_第4页

Clinical efficacy and safety profile of long-acting lipoglycopeptides versus daily intravenous antibiotics for acute bacterial skin and skin structure infections (ABSSSI): a retrospective study in Greece. 长效脂糖肽与每日静脉注射抗生素治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的临床疗效和安全性：希腊的一项回顾性研究。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-08-03 DOI: 10.1080/1120009X.2026.2710944

Vasileios Petrakis, Andreas G Tsantes, Petros Rafailidis, Maria Panopoulou, Touba Bougiouklou, Georgios Karagiannis, Anastasia Sousanidou, Nikoleta Babaka, Dimitrios Papazoglou, Periklis Panagopoulos

{"title":"Clinical efficacy and safety profile of long-acting lipoglycopeptides versus daily intravenous antibiotics for acute bacterial skin and skin structure infections (ABSSSI): a retrospective study in Greece.","authors":"Vasileios Petrakis, Andreas G Tsantes, Petros Rafailidis, Maria Panopoulou, Touba Bougiouklou, Georgios Karagiannis, Anastasia Sousanidou, Nikoleta Babaka, Dimitrios Papazoglou, Periklis Panagopoulos","doi":"10.1080/1120009X.2026.2710944","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2710944","url":null,"abstract":"Background: The rising prevalence of antimicrobial resistance poses a significant challenge in clinical practice, with long-acting lipoglycopeptides (LGPs) offering an attractive alternative to conventional daily intravenous antibiotics. This study aims to evaluate the clinical efficacy, safety, and economic burden of LGPs in the treatment of skin and soft tissue infections.Methods: This was a retrospective, single-centre, observational study including 125 patients with skin and soft tissue infections who were either treated with LGPs such as dalbavancin or oritavancin (Group A, n = 62), or with standard daily IV therapy including vancomycin, linezolid, or daptomycin (Group B, n = 63). The primary outcome was clinical improvement, while secondary outcomes included length of hospital stay, adverse events, and relapse rate during a 28-day period.Results: The overall clinical success rate was comparable between the two groups (Group A: 95.1% vs. Group B: 92.0%, p = 0.11). However, patients treated with LGPs demonstrated a shorter median hospital stay (Group A: 5.5 days vs. Group B: 11.0 days, p < 0.001), which was also correlated with a lower average cost of hospitalization. Furthermore, the incidence of adverse events was lower in the LGP group (Group A: 8.06% vs. Group B: 25.4%).Conclusion: Long-acting lipoglycopeptides demonstrated comparable clinical success rates to conventional daily intravenous antibiotics for the treatment of ABSSSI, with a 'favorable safety profile.' Moreover, the reduced cost and shorter hospitalization further support the use of LGPs as a safe and effective alternative for managing these infections.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer. TROP2抗体-药物偶联方案在HER2阴性转移性乳腺癌和晚期非小细胞肺癌患者中的疗效和安全性

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-29 DOI: 10.1080/1120009X.2026.2708448

Yangqingqing Zhou, Wunan Huang, Hui Wang, Xinyue Hang, Haitao Jin, Ruiyuan He, Chaosheng Gan

{"title":"Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer.","authors":"Yangqingqing Zhou, Wunan Huang, Hui Wang, Xinyue Hang, Haitao Jin, Ruiyuan He, Chaosheng Gan","doi":"10.1080/1120009X.2026.2708448","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2708448","url":null,"abstract":"The aim of this study is to evaluate the efficacy and safety of TROP2 antibody-drug conjugate (ADC) -based regimen in the treatment of HER2-negative advanced breast cancer and non-small cell lung cancer (NSCLC) in real environment to fill the evidence gap. A total of 130 patients (median age 55 years) were included in the study. The median progression-free survival (mPFS) of 75 NSCLC patients was 10.0 (95%CI: 5.130-14.870) months. The mPFS of 21 hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) patients was 6.0 (95%CI: 4.217-7.783) months. The mPFS of 34 triple-negative breast cancer (TNBC) patients was 5.0 (95%CI: 2.845-7.158) months. In patients with TNBC, mPFS was significantly shorter with sacituzumab govitecan monotherapy than with sacituzumab tirumotecan monotherapy (2.0 months vs 6.0 months, p = 0.036). In patients with NSCLC, mPFS was significantly longer in those receiving sacituzumab tirumotecan monotherapy as first-and second-line therapy than in those receiving third-line or more therapy (17.0 vs 7.0 months, p = 0.0026). The incidence of adverse events was 63.8% (≥ grade 3 accounted for 38.5%), mainly anemia, leukopenia, etc. The existing evidence suggests that TROP2 ADC has certain anti-tumor activity in advanced HER2-negative breast cancer and NSCLC, which provides limited support for its exploration in first-line combination and early treatment. However, the actual improvement effect on survival endpoints is still unclear and needs to be verified by large prospective phase III studies. At the same time, long-term safety signals and acquired drug resistance also need continuous attention.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of PD-1/PD-L1 inhibitor-combined chemotherapy versus chemotherapy alone in extensive-stage small-cell lung cancer: a meta-analysis. PD-1/PD-L1抑制剂联合化疗与单独化疗治疗广泛期小细胞肺癌的疗效和安全性：一项荟萃分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-15 DOI: 10.1080/1120009X.2026.2701506

Qiuyi Li, Dan Yan, Wei Li, Yu Liu

引用次数: 0

A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study. 1:1:1倾向评分匹配设计，以解释观察性研究中中心特异性抗菌治疗或预防：POSACOVID研究的案例。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-13 DOI: 10.1080/1120009X.2026.2700064

Cristina Marelli, Daniele Roberto Giacobbe, Alessio Signori, Juergen Prattes, Silvia Dettori, Greta Cattardico, Stefan Hatzl, Alexander C Reisinger, Philipp Eller, Robert Krause, Florian Reizine, Jean-Pierre Gangneux, Martin Hoenigl, Matteo Bassetti

{"title":"A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study.","authors":"Cristina Marelli, Daniele Roberto Giacobbe, Alessio Signori, Juergen Prattes, Silvia Dettori, Greta Cattardico, Stefan Hatzl, Alexander C Reisinger, Philipp Eller, Robert Krause, Florian Reizine, Jean-Pierre Gangneux, Martin Hoenigl, Matteo Bassetti","doi":"10.1080/1120009X.2026.2700064","DOIUrl":"10.1080/1120009X.2026.2700064","url":null,"abstract":"Propensity score matching (PSM) is employed in observational studies to reduce confounding by baseline characteristics. We considered a scenario where one center administered a given treatment/prophylaxis, and two other centers provided standard-of-care. We aimed to develop a three-group matching method balancing measured confounders between treated and control subjects while preserving center-effects, since they represent the effect of treatment/prophylaxis in the given scenario. Using multinomial logistic regression, we estimated generalized propensity scores and matched patient triplets by minimizing the perimeter of the triangle formed by their scores. We compared this method to classical 1:1 PSM in both a simulation and a case study (the POSACOVID study). While 1:1 PSM showed better balance, only 1:1:1 PSM balanced the two control groups and preserved center-effects. Overall, 1:1:1 PSM may be preferable when is essential to preserve center-specific characteristics influencing the treatment allocation and then to balance multiple control groups despite increased computational cost.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-16"},"PeriodicalIF":2.1,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking antibiotic use in hidradenitis suppurativa: a call for stewardship. 对化脓性汗腺炎抗生素使用的反思：呼吁管理。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-10-23 DOI: 10.1080/1120009X.2025.2572884

E Rosi, G Silvi, A Di Cesare, F Prignano

引用次数: 0

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma. 索托拉西布联合多西他赛治疗KRAS G12C突变型肺腺癌克服索托拉西布单用耐药

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-05-12 DOI: 10.1080/1120009X.2025.2503052

Chia-Yu Kuo, Tzu-Wen Wang, Ann-Shung Lieu, Chih-Jen Yang

引用次数: 0

Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections. 噬菌体治疗在临床中的应用：铜绿假单胞菌感染病例研究。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-08-14 DOI: 10.1080/1120009X.2025.2547147

Ahmed Elfadadny, Rokaia F Ragab, Osama Aldesoky Abd Alaziz, Habiba Y Essa, Esraa M Eltony, Mohamed M Ammar, Wedad M Nageeb

引用次数: 0

Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway. Chidamide通过抑制METTL3/EPHA7通路阻碍非小细胞肺癌的进展。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-06-30 DOI: 10.1080/1120009X.2025.2522508

Teng Ren, Hongpei Zhang, Yurou Liu, Juan Wang, Miaomiao Liu, Yanli Chen

{"title":"Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway.","authors":"Teng Ren, Hongpei Zhang, Yurou Liu, Juan Wang, Miaomiao Liu, Yanli Chen","doi":"10.1080/1120009X.2025.2522508","DOIUrl":"10.1080/1120009X.2025.2522508","url":null,"abstract":"Chidamide, a histone deacetylase inhibitor with established anti-tumor properties, requires further investigation regarding its specific impact on lung cancer progression. Our results showed that chidamide treatment significantly inhibited proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells while inducing apoptosis. The treatment with chidamide also downregulated methyltransferase 3 (METTL3), the catalytic subunit of the N6-adenosine-methyltransferase complex, in A549 and H1299 cells. Overexpression of METTL3 reversed the inhibitory effects of chidamide on NSCLC cell progression. Furthermore, we found that METTL3 stabilized EPH receptor A7 (EPHA7) expression through an m6A-dependent mechanism. Conversely, overexpression of EPHA7 counteracted the effects of METTL3 silencing or chidamide treatment in both cell lines. In vivo, chidamide treatment reduced EPHA7 protein expression by regulating METTL3, leading to inhibited tumor growth. Collectively, these findings identified the METTL3/EPHA7 axis as a key mediator of chidamide's anti-tumor effects, suggesting chidamide's potential as a novel therapeutic strategy for NSCLC.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"377-388"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Docetaxel associated myositis. 多西紫杉醇相关性肌炎。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-05-20 DOI: 10.1080/1120009X.2025.2505806

Nadide Demırel, Metin Demır

{"title":"Docetaxel associated myositis.","authors":"Nadide Demırel, Metin Demır","doi":"10.1080/1120009X.2025.2505806","DOIUrl":"10.1080/1120009X.2025.2505806","url":null,"abstract":"Introducti̇on: Docetaxel is a microtubule inhibitor in the taxane group and it is a semisynthetic analogue of paclitaxel. It binds to β-tubulin subunits with high affinity, preventing the depolymerization of microtubules during metaphase. Myalgia has been frequently described as a docetaxel-related side effect. However, myositis is a rare side effect of docetaxel.Case report: A 64-year-old female patient with a right breast mass was diagnosed with invasive breast cancer. The tumor was 100% and 60% positive for estrogen and progesterone receptor, respectively and human epidermal growth factor receptor 2 (HER-2) was positive. There was not any distant metastasis in screening. It was clinically staged as T4N0M0 (stage 3B). Treatment was started with neoadjuvant chemotherapy (CT) as docetaxel plus trastuzumab (TR) plus pertuzumab. The patient applied to the outpatient clinic with muscle pain and weakness which started a few days after the second CT cycle.Management & outcome: The neurological physical exam was normal except that the muscle strength was 1/5 in the lower extremities with tense swelling. Joint pain or skin lesions were absent. Laboratory results revealed creatine kinase (CK) 4389 U/L. The patient was hospitalized with the diagnosis of myositis/myopathy due to these findings. Autoimmune markers were in normal range. The lower extremity magnetic resonance imaging (MRI) showed intense edema. The patient underwent a muscle biopsy. These findings were compatible with drug-associated necrotizing myopathy.Di̇scussi̇on: Docetaxel-related myositis is a rare complication and clinicians should be aware of this adverse event in patients with suspicious symptoms and with comorbidities.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"404-409"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells. Cinobufagin调节microRNA-149-3p/AFF4轴影响顺铂耐药卵巢癌细胞的增殖和凋亡。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-05-27 DOI: 10.1080/1120009X.2025.2508614

Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang

{"title":"Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells.","authors":"Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang","doi":"10.1080/1120009X.2025.2508614","DOIUrl":"10.1080/1120009X.2025.2508614","url":null,"abstract":"Although cinobufagin has been demonstrated to inhibit the growth of various malignant tumors, its functional role in ovarian cancer remains unclear. In light of this, the present study aims to thoroughly investigate the effects of cinobufagin on ovarian cancer progression and elucidate its underlying molecular mechanisms, thereby providing novel insights into future therapeutic strategies. A2780/DDP, a cisplatin-resistant cell line for ovarian cancer, was treated with gradient doses of cinobufagin. The microRNA-149-3p and AFF4 binding sites were predicted by bioinformatics. In cisplatin-resistant ovarian cancer cells, microRNA-149-3p and AFF4 expression were detected using qRT-PCR, and the binding association between microRNA-149-3p and AFF4 was confirmed by dual-luciferase and RIP assays. Cell viability was assessed using the CCK-8 test, cell proliferation was identified using the EdU assay and colony formation, and cell apoptosis was identified using flow cytometry. The results showed that cinobufagin inhibited the proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. microRNA-149-3p was highly expressed in cisplatin-resistant ovarian cancer cells, while AFF4 was lowly expressed in these cells. Overexpression of microRNA-149-3p promoted the proliferation and inhibited the apoptosis of cisplatin-resistant ovarian cancer cells, which was reversed by the addition of cinobufagin. Overexpression of AFF4 suppressed proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. MicroRNA-149-3p repressed AFF4 expression, and partial attenuation of the effects of AFF4 overexpression on cell phenotype was observed when microRNA-149-3p was overexpressed. In conclusion,cinobufagin regulated microRNA-149-3p/AFF4 axis to inhibit proliferation of ovarian cancer cells and promote cell apoptosis. Targeting the microRNA-149-3p/AFF4 axis with cinobufagin could represent a novel therapeutic strategy for ovarian cancer.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"345-354"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0